Sign inJoin waitlistJoin the waitlist

Antoni Ribas

Director of the Tumor Immunology Program · Jonsson Comprehensive Cancer Center

Credentials: · · ·

History

Tumor Immunology Program · Jonsson Comprehensive Cancer Center
Present
Parker Institute for Cancer Immunotherapy (PICI) Center · UCLA
Present
University of California Los Angeles
Present

UCLA School of Medicine
Until 2001
UCLA School of Medicine
Until 1998
Hospital Vall d'Hebron
Until 1994
Hospital Vall d'Hebron
Until 1991
Universidad de Barcelona
1990

Research

Improved survival with vemurafenib in melanoma with BRAF V600E mutation
New England Journal of Medicine · 2011 · 6,152 citations
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Nature · 2014 · Last of 26 authors · 5,545 citations
Cancer immunotherapy using checkpoint blockade
Review · Science · 2018 · First of 2 authors · Corresponding · 5,365 citations

Bartosz Chmielowski
55 papers
James Economou
54 papers
Keith Flaherty
54 papers
John Glaspy
50 papers
Jeffrey Sosman
47 papers
Roger Lo
43 papers
John Kirkwood
32 papers
Omid Hamid
31 papers
Siwen Hu-Lieskovan
30 papers · 25 as a resident
Jedd Wolchok
27 papers
Stephen Hodi
27 papers
Adil Daud
26 papers

Grants

Cancer Center Support Grant
National Cancer Institute · P30
Project lead · $819.2K · University of California Los Angeles
1996–2030
Next Generation Cancer Immunotherapies to Defeat Melanoma
National Cancer Institute · R35
Contact PI · $10.4M · University of California Los Angeles
2015–2029
Combination Therapies to Defeat Melanoma Resistance
National Cancer Institute · P01
Contact PI · $12.8M · University of California Los Angeles
2020–2025
Repurposing of Cancer Therapeutics for Treatment of Patients with COVID-19 Disease
National Cancer Institute · U54
PI · $2.2M · Institute for Systems Biology
2015–2021

Clinical trials

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Principal investigator · Recruiting · Phase 1
Anusha Kalbasi
2025–2026
Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma
Principal investigator · Terminated · Phase 1
Jonsson Comprehensive Cancer Center
2018–2021
PET Imaging of the Immune System Using Analog Probes
Principal investigator · Completed
Jonsson Comprehensive Cancer Center
2018–2020
Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1
Principal investigator · Completed · Phase 1
Jonsson Comprehensive Cancer Center
2017–2019